Efficacy of intentional permanent atrial pacing in the long‐term management of congenital long QT syndrome. (10th February 2021)

• Record Type: Journal Article
• Authors: Kowlgi, Gurukripa N.; Giudicessi, John R.; Barake, Walid; Bos, J. Martijn; Ackerman, Michael J.
• Is Part Of: Journal of cardiovascular electrophysiology. Volume 32:Number 3(2021)
• Page Start: 782
• Page End: 789
• Publication Date: 2021-02-10
• Subjects: atrial pacing -- congenital long QT syndrome -- implantable cardioverter‐defibrillator -- ventricular arrhythmias; Blood vessels -- Physiology -- Periodicals; Electrophysiology -- Periodicals; Heart -- Physiology -- Periodicals; 612.1
• DOI: 10.1111/jce.14920
• Languages: English
• ISSNs: 1045-3873

Abstract

Abstract: Background: Unfortunately, some patients with long QT syndrome (LQTS) experience breakthrough cardiac events (BCEs) despite maximal therapy. Small studies have shown that refractory LQTS cases may benefit from intentional permanent atrial pacing (IPAP). As such, we sought to determine the genotype‐specific utilization and efficacy of IPAP in a single‐center LQTS registry. Methods and Results: In this retrospective study, electronic medical records from 1065 patients diagnosed with LQTS were used to identify individuals that received IPAP. Pre‐ and post‐IPAP heart rate, heart rate‐corrected QT (QTc) values, annual BCE rate, and IPAP‐related complications were compared between genotypes. BCEs were defined as LQTS‐associated syncope/seizures, sustained ventricular arrhythmia (VA)‐terminating ICD therapies, and sudden cardiac arrest/death. Overall, 52 out of 1065 LQTS patients received adjunctive IPAP therapy (77% female; median age 18.5 [interquartile range, 1–35.5] years; 73% with prior VA). Over an average IPAP follow‐up of 121 ± 82 months, the average heart rate increased from 65.8 ± 20.4 bpm to 78.9 ± 17.1 bpm; ( p < .01) and the average QTc decreased from 533.4 ± 66.6 to 488.3 ± 52.4 ms; ( p < .01). The mean BCE rate dropped from 0.88 to 0.19 per patient‐year ( p = .01), driven by a marked decrease in the LQT2 cohort (1.01 BCE/year to 0.02 BCE/year; p = .003). No serious IPAP‐related complications were observed. Conclusion: In high‐risk LQTS patients, namely those with recalcitrant LQT2, IPAP appears to be a safe and efficacious adjunct therapy. The beneficial effects of IPAP may stem from attenuating the QTc and circumventing a pause‐dependent trigger. Whether IPAP might obviate the need for an ICD in some instances warrants further study.